Search results for "Blood glucose"

showing 10 items of 437 documents

Altered adipose tissue metabolism in offspring of dietary obese rat dams.

2011

To investigate further the mechanisms of developmental programming, we analysed the effects of maternal overnutrition and of postnatal high-fat feeding on adipose tissue metabolism in the offspring. Postnatal changes in serum adiponectin, leptin and TAG [triacylglycerol (triglyceride)] levels, adipose tissue TAGs, fatty acids and enzyme activities were determined in offspring of cafeteria-diet-fed dams during gestation and lactation, weaned on to standard chow or on to cafeteria diet. Obese rats showed higher adiposity (+35% to 85%) as well as a significant increase in serum glucose, insulin, leptin, adiponectin and TAG levels (P<0.01) and adipose tissue LPL (lipoprotein lipase) and …

Blood Glucosemedicine.medical_specialtyOffspringAdipokineAdipose tissueBiologychemistry.chemical_compoundOvernutritionPregnancyInternal medicinemedicineAdipocytesAnimalsObesityRats WistarPrenatal Nutritional Physiological PhenomenaTriglycerideschemistry.chemical_classificationTriglycerideAdiponectinLeptinBody WeightFatty AcidsGeneral MedicineFeeding BehaviorOrgan Sizemedicine.diseaseHormonesRatsPregnancy ComplicationsEndocrinologychemistryAdipose TissuePrenatal Exposure Delayed EffectsFemalePolyunsaturated fatty acidClinical science (London, England : 1979)
researchProduct

Peroxisome Proliferator-Activated Receptor Deficiency Increases the Risk of Maternal Abortion and Neonatal Mortality in Murine Pregnancy with or with…

2006

We assessed the implication of peroxisome proliferator-activated receptor (PPAR) alpha deficiency in pregnancy outcome and neonatal survival and in the modulation of T cell differentiation in murine diabetic pregnancy and their offspring. Pregnant wild-type (WT) and PPAR alpha-null mice of C57BL/6J genetic background were rendered diabetic by five low doses of streptozotocin. We observed that, in the absence of diabetes, PPAR alpha deficiency resulted in an increase in abortion rate, i.e. 0% in WT mice vs. 20% in PPAR alpha-null mice [odds ratio (OR) = 14.33; P = 0.013]. Under diabetic conditions, the abortion rate was enhanced, i.e. 8.3% in WT mice vs. 50% in PPAR alpha-null mice (OR = 4.2…

Blood Glucosemedicine.medical_specialtyOffspringRatónT-LymphocytesPeroxisome proliferator-activated receptorBiologyPeroxisomeDiabetes Mellitus ExperimentalInterferon-gammaMiceEndocrinologyTh2 CellsDownregulation and upregulationPregnancyDiabetes mellitusInternal medicinemedicineAnimalsInsulinPPAR alphaLymphocyte CountRNA MessengerReceptorFetal Deathchemistry.chemical_classificationMice KnockoutPregnancy[SCCO.NEUR]Cognitive science/NeuroscienceCell DifferentiationTh1 CellsStreptozotocinmedicine.diseaseLipidsInterleukin-10Abortion SpontaneousMice Inbred C57BLPregnancy ComplicationsEndocrinologychemistry[ SCCO.NEUR ] Cognitive science/NeuroscienceCytokinesInterleukin-2FemaleInterleukin-4Spleenmedicine.drug
researchProduct

Modulation of lipid metabolism by n-3 polyunsaturated fatty acids in gestational diabetic rats and their macrosomic offspring.

2005

The time course of changes in lipid metabolism by dietary n−3 PUFAs (polyunsaturated fatty acids) in streptozotocin-induced diabetic rats during pregnancy (days 12 and 21) and their macrosomic offspring at birth (day 0) and through adulthood (days 60 and 90) was studied with respect to adipose tissue, liver and serum lipid concentrations, and fatty acid composition. Glucose and insulin levels were also assessed in order to characterize the diabetic state of macrosomic offspring. Pregnant diabetic and control rats were fed either an Isio-4 or EPAX diet (enriched with n−3 PUFA). The same diets were also consumed by pups at weaning. Compared with control rats, during pregnancy diabetic rats ha…

Blood Glucosemedicine.medical_specialtyOffspringmedicine.medical_treatmentBiologyDiabetes Mellitus ExperimentalFetal Macrosomiachemistry.chemical_compoundDietary Fats UnsaturatedPregnancyDiabetes mellitusInternal medicinemedicineAnimalsInsulinRats Wistarchemistry.chemical_classificationTriglycerideCholesterolInsulinBody WeightLipid metabolismGeneral MedicineOrgan Sizemedicine.diseaseLipid MetabolismRatsDiabetes GestationalEndocrinologychemistryAdipose TissueAnimals NewbornLiverDocosahexaenoic acidlipids (amino acids peptides and proteins)FemalePolyunsaturated fatty acidClinical science (London, England : 1979)
researchProduct

Correlation between periodontal disease management and metabolic control of type 2 diabetes mellitus: a systematic literature review

2016

Background: Diabetes and periodontal disease share common features in terms of inflammatory responses. Current scientific evidence suggests that treatment of periodontal disease might contribute to glycemic control. The objective of the study is a review of the last three years. Material and Methods: A literature search was performed in the MEDLINE (PubMed), Cochrane, and Scopus databases, for articles published between 01-01-2013 and 30-06-2015, applying the key terms “periodontal disease” AND “diabetes mellitus”. The review analyzed clinical trials of humans published in English and Spanish. Results: Thirteen clinical trials were reviewed, representing a total of 1,912 patients. Three of …

Blood Glucosemedicine.medical_specialtyPathologyMEDLINEOdontologíaReviewMalalties periodontals03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicinemedicineHumans030212 general & internal medicineGeneral DentistryPeriodontal DiseasesGlycemicGlycated HemoglobinClinical Trials as TopicOral Medicine and PathologyDiabetisbusiness.industryDiabetesType 2 Diabetes Mellitus030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludJadad scaleClinical trialSystematic reviewGlucoseOtorhinolaryngologyDiabetes Mellitus Type 2Metabolic control analysisUNESCO::CIENCIAS MÉDICASGlucosaSurgeryPeriodontal diseasebusiness
researchProduct

Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics.

2001

Background. The aim of the present study was to assess the antialbuminuric effect of losartan in a large number of hypertensive type 2 diabetics. Methods. This was a 6-month, open-label, prospective and multicentre study. A total of 422 patients with type 2 diabetes who were hypertensive [sitting systolic blood pressure (SBP) > 140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg] and microalbuminuric [urinary albumin excretion (UAE) 30-300 mg/day] were eligible for the study. After a 2-week run-in period, patients were placed on losartan 50 mg once a day. If the BP did not reach the desired goal (<140/90 mmHg) after a 4-week period, the losartan dose was doubled. In the absence of contr…

Blood Glucosemedicine.medical_specialtySystoleUrologyRenal functionBlood PressureType 2 diabetesLosartanDiabetic nephropathyDiastoleDiabetes mellitusInternal medicinemedicineAlbuminuriaHumansAntihypertensive AgentsGlycated HemoglobinTransplantationbusiness.industryBody Weightmedicine.diseaseAngiotensin IIUric AcidLosartanEndocrinologyBlood pressureHydrochlorothiazideDiabetes Mellitus Type 2NephrologyHypertensionRegression AnalysisMicroalbuminuriaDrug Therapy CombinationbusinessDiabetic Angiopathiesmedicine.drugNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
researchProduct

Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproteron…

2017

Abstract Background Although oral contraceptives (OCs) are the most common treatment in women with polycystic ovary syndrome (PCOS), their effects and safety on the metabolic profiles of these patients are relatively unknown. In this meta-analysis the effects of the different durations (from 3 months to 1 year) of OC treatment using cyproterone acetate (CA) or third generation progestins on metabolic profile of patients with PCOS were assessed. Materials and methods PubMed, Scopus, Google Scholar and ScienceDirect databases (2001–2015) were searched to identify clinical trials investigating the effects of OC containing CA or third generation progestins on metabolic profiles of women with PC…

Blood Glucosemedicine.medical_specialtyTime Factorsmedicine.drug_classEndocrinology Diabetes and MetabolismBlood lipidsBlood Pressure030209 endocrinology & metabolism03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInsulin resistanceDesogestrelInternal medicinemedicineHumansInsulinCyproterone AcetateClinical Trials as Topic030219 obstetrics & reproductive medicinebusiness.industryBody WeightCyproterone acetateDrospirenoneLipid Metabolismmedicine.diseasePolycystic ovaryEndocrinologychemistryMetabolomeFemaleProgestinsbusinessProgestinBody mass indexContraceptives OralPolycystic Ovary Syndromemedicine.drugMetabolism
researchProduct

Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozinvsplacebo or empagliflozin in patients with type 2 diabetes and heart f…

2020

Aims Explore the efficacy, safety and tolerability of the dual sodium-glucose cotransporter (SGLT) 1 and 2 inhibitor, licogliflozin in patients with type-2 diabetes mellitus (T2DM) and heart failure. Methods This multicentre, parallel-group phase IIA study randomized 125 patients with T2DM and heart failure (New York Heart Association II-IV; plasma N-terminal pro b-type natriuretic peptide [NT-proBNP] &gt;300 pg/mL) to licogliflozin (2.5 mg, 10 mg, 50 mg) taken at bedtime, empagliflozin (25 mg) or placebo (44 patients completed the study). The primary endpoint was change from baseline in NT-proBNP after 12 weeks. Secondary endpoints included change from baseline in glycated haemoglobin, fas…

Blood Glucosemedicine.medical_specialtyUrologyheart failureType 2 diabetesPlacebo030226 pharmacology & pharmacyBedtimeAnhydridesSGLT2 INHIBITORS03 medical and health sciencespharmacotherapy0302 clinical medicineDouble-Blind MethodGlucosidesDiabetes mellitusmedicineEmpagliflozinHumansHypoglycemic AgentsSorbitolPharmacology (medical)030212 general & internal medicineCOTRANSPORTER 2 INHIBITORSBenzhydryl CompoundsPharmacologyGlycated HemoglobinOUTCOMESbusiness.industrySodiumbiomarkersOriginal Articlesmedicine.diseaseEFFICACYBlood pressureGlucoseTreatment OutcomeTolerabilityDiabetes Mellitus Type 2PRESERVED EJECTION FRACTIONHeart failureSAFETYOriginal Articlebiomarkers heart failure pharmacotherapy type 2 diabetestype 2 diabetesbusinessBritish Journal of Clinical Pharmacology
researchProduct

Psychosocial Aspects of Continuous Glucose Monitoring

2016

Continuous glucose monitoring (CGM) systems provide people with diabetes with valuable real-time information on glucose trajectories and trends, thus offering opportunities for improving diabetes self-management. Ample evidence from clinical trials underscores CGM effectiveness for biomedical outcomes including HbA1C and hypoglycemia. However, interindividual variability in CGM uptake seems to be substantial: Neither do all individuals with diabetes adopt CGM readily in their diabetes self-management, nor do all of them benefit from CGM. In this article, we focus on CGM effects on quality of life and the potential role of psychosocial patient characteristics for determining the uptake and …

Blood Glucosemedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismBiomedical EngineeringPatient characteristics030209 endocrinology & metabolismBioengineeringHypoglycemia03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Diabetes mellitusDiabetes MellitusInternal MedicinemedicineHumans030212 general & internal medicineSpecial Section: Psychological Factors for Diabetes Technology Part IIIntensive care medicineContinuous glucose monitoringbusiness.industryBlood Glucose Self-Monitoringnutritional and metabolic diseasesmedicine.diseaseClinical diabetesClinical trialQuality of LifebusinessPsychosocialJournal of Diabetes Science and Technology
researchProduct

Irisinemia: A Novel Concept to Coin in Clinical Medicine?

2013

Skeletal muscle can express and release substances such as cytokines or other peptides capable of modulating metabolic processes. These cytokines, named ‘myokines', function as hormones either locally within the muscle or by targeting distant organs. A novel peptidic myokine named ‘irisin' has been recently identified. It has been noted that circulating irisin levels are lower in type 2 diabetes (T2D) compared with nondiabetic controls as well as in patients with chronic kidney disease. In addition, a negative correlation between the hemoglobin A1c (HbA1c) and circulating levels of irisin has been also observed. Thus, the blood concentration of irisin may reflect the metabolic status of pat…

Blood Glucosemedicine.medical_specialtyendocrine system diseasesMedicine (miscellaneous)Type 2 diabetesMetabolic DiseasesDiabetes mellitusInternal medicineMyokineHumansMedicineObesityRenal Insufficiency ChronicMuscle SkeletalNutrition and Dieteticsbusiness.industrynutritional and metabolic diseasesSkeletal musclemedicine.diseaseObesityFibronectinsMetabolism disorderEndocrinologymedicine.anatomical_structureDiabetes Mellitus Type 2ImmunologyCytokinesbusinessHormoneKidney diseaseAnnals of Nutrition and Metabolism
researchProduct

Correction of glycaemia and GLUT1 level by mildronate in rat streptozotocin diabetes mellitus model

2011

Anti-ischaemic drug mildronate suppresses fatty acid metabolism and increases glucose utilization in myocardium. It was proposed that it could produce a favourable effect on metabolic parameters and glucose transport in diabetic animals. Rats with streptozotocin diabetes mellitus were treated with mildronate (100 mg/kg daily, per os, 6 weeks). Therapeutic effect of mildronate was monitored by measuring animal weight, concentrations of blood glucose, insulin, blood triglycerides, free fatty acids, blood ketone bodies and cholesterol, glycated haemoglobin per cent (HbA1c%) and glucose tolerance. GLUT1 mRNA and protein expression in kidneys, heart, liver and muscles were studied by means of re…

Blood Glucosemedicine.medical_specialtyendocrine system diseasesmedicine.medical_treatmentClinical BiochemistryBiochemistryStreptozocinDiabetes Mellitus Experimentalchemistry.chemical_compoundInternal medicineDiabetes mellitusDiabetes MellitusmedicineAnimalsBody SizeHypoglycemic AgentsInsulinRNA MessengerRats WistarTriglyceridesGlycated HemoglobinGlucose Transporter Type 1Glucose tolerance testmedicine.diagnostic_testFatty acid metabolismbiologyCholesterolbusiness.industryInsulinFatty AcidsGlucose transporternutritional and metabolic diseasesCell BiologyGeneral MedicineGlucose Tolerance Testmedicine.diseaseRatsEndocrinologychemistrybiology.proteinKetone bodiesGLUT1businessMethylhydrazinesCell Biochemistry and Function
researchProduct